Pharma tariffs pressuring smaller companies to do MFN deals

The Trump administration’s new pharmaceutical tariffs are aimed at coercing drugmakers into “most favored nation” pricing agreements, accelerating the onshoring of manufacturing, and building political momentum to codify the temporary MFN pricing framework into law.

The tariffs target biopharma companies that have not yet agreed to MFN deals. Mid-sized and smaller companies that rely on manufacturing outside the U.S., especially China, face intense pressure to agree to “voluntary” price controls. ...